Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Migration and Proliferation Effects of Thymoquinone-Loaded Nanostructured Lipid Carrier (TQ-NLC) and Thymoquinone (TQ) on In Vitro Wound Healing Models.

Alexander HR, Syed Alwi SS, Yazan LS, Zakarial Ansar FH, Ong YS.

Evid Based Complement Alternat Med. 2019 Nov 29;2019:9725738. doi: 10.1155/2019/9725738. eCollection 2019.

2.

The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype.

Kandasamy S, Adhikary G, Rorke EA, Friedberg JS, Mickle MB, Alexander HR, Eckert RL.

Mol Cancer Res. 2019 Nov 15. doi: 10.1158/1541-7786.MCR-19-0914. [Epub ahead of print]

PMID:
31732616
3.

Defining and Refining the Role for Surgery and Intraperitoneal Chemotherapy in the Treatment of Peritoneal Surface Malignancies.

Choudry MH, Bartlett DL, Alexander HR, Turaga KK.

Ann Surg Oncol. 2020 Jan;27(1):73-75. doi: 10.1245/s10434-019-07956-x. Epub 2019 Oct 23. No abstract available.

PMID:
31646448
4.

NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer.

Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J, Ströbel P, Azizian A, Ried T, Gaida MM, Yfantis HG, Lee DH, Lal A, Van den Eynde BJ, Alexander HR, Ghadimi BM, Hanna N, Hussain SP.

Int J Cancer. 2019 Oct 14. doi: 10.1002/ijc.32733. [Epub ahead of print]

PMID:
31609478
5.

Outcomes Following Major Oncologic Operations for Non-AIDS-Defining Cancers in the HIV Population: A Matched Comparison to the General Population.

Chi A, Adams BE, Sesti J, Paul S, Turner AL, August D, Carpizo D, Kennedy T, Grandhi M, Alexander HR, Libutti SK, Geffner S, Langan RC.

World J Surg. 2019 Dec;43(12):3019-3026. doi: 10.1007/s00268-019-05151-3.

PMID:
31493193
6.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8. Review.

7.

It Is Time.

Turaga KK, Gamblin TC, Edwards R, Alexander HR, Bartlett D.

Ann Surg Oncol. 2019 Jul;26(7):1963-1966. doi: 10.1245/s10434-019-07207-z. Epub 2019 Apr 29. No abstract available.

PMID:
31037435
8.

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation.

Adhikary G, Grun D, Alexander HR, Friedberg JS, Xu W, Keillor JW, Kandasamy S, Eckert RL.

Oncotarget. 2018 Oct 2;9(77):34495-34505. doi: 10.18632/oncotarget.26130. eCollection 2018 Oct 2.

9.

Peritoneal Metastases from Malignant Mesothelioma.

Li CY, Alexander HR Jr.

Surg Oncol Clin N Am. 2018 Jul;27(3):539-549. doi: 10.1016/j.soc.2018.02.010. Review.

PMID:
29935688
10.

Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome.

Norton JA, Krampitz GW, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT.

Ann Surg. 2018 Apr;267(4):782-788. doi: 10.1097/SLA.0000000000002122.

PMID:
29517561
11.

Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma.

Alexander HR Jr, Li CY, Kennedy TJ.

Ann Surg Oncol. 2018 Aug;25(8):2159-2164. doi: 10.1245/s10434-018-6337-5. Epub 2018 Feb 8. Review.

PMID:
29423664
12.

Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.

Norton JA, Foster DS, Blumgart LH, Poultsides GA, Visser BC, Fraker DL, Alexander HR, Jensen RT.

JAMA Surg. 2018 Mar 1;153(3):e175083. doi: 10.1001/jamasurg.2017.5083. No abstract available.

13.

Current management strategies for peritoneal mesothelioma.

Turaga KK, Deraco M, Alexander HR.

Int J Hyperthermia. 2017 Aug;33(5):579-581. doi: 10.1080/02656736.2017.1320591. Review.

PMID:
28664790
14.

Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy.

Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M.

J Oncol Pract. 2016 Oct;12(10):928-935.

PMID:
27858561
15.

Rapid progression of a pregnancy-associated intra-abdominal desmoid tumor in the post-partum period: A case report.

Hanna D, Magarakis M, Twaddell WS, Alexander HR, Kesmodel SB.

Int J Surg Case Rep. 2016;29:30-33. doi: 10.1016/j.ijscr.2016.10.056. Epub 2016 Oct 26.

16.

Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.

Wang J, Yang S, He P, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2016 Dec 15;22(24):5992-6001. Epub 2016 Jul 8.

17.

Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer.

Wang J, He P, Gaida M, Yang S, Schetter AJ, Gaedcke J, Ghadimi BM, Ried T, Yfantis H, Lee D, Weiss JM, Stauffer J, Hanna N, Alexander HR, Hussain SP.

Oncotarget. 2016 Aug 16;7(33):52993-53004. doi: 10.18632/oncotarget.10323.

18.

A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.

Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Yanaga K, Uwagawa T, Satoskar AR, Gaedcke J, Bernhardt M, Ghadimi BM, Gaida MM, Bergmann F, Werner J, Ried T, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2016 Jul 1;76(13):3838-50. doi: 10.1158/0008-5472.CAN-15-2841. Epub 2016 Apr 20.

19.

Diagnosis and management of patients with malignant peritoneal mesothelioma.

Alexander HR Jr, Burke AP.

J Gastrointest Oncol. 2016 Feb;7(1):79-86. doi: 10.3978/j.issn.2078-6891.2015.134. Review.

20.

Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective.

Neuwirth MG, Alexander HR, Karakousis GC.

J Gastrointest Oncol. 2016 Feb;7(1):18-28. doi: 10.3978/j.issn.2078-6891.2015.106. Review.

21.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy.

Karakousis GC, Alexander HR.

J Gastrointest Oncol. 2016 Feb;7(1):1-2. doi: 10.3978/j.issn.2078-6891.2015.133. No abstract available.

22.

Regional Therapies for Advanced Cancer: Update for 2016.

Turaga KK, Gamblin TC, Alexander HR, Edwards R, Bartlett DL.

Ann Surg Oncol. 2016 May;23(5):1452-3. doi: 10.1245/s10434-015-5068-0. Epub 2016 Jan 5. No abstract available.

PMID:
26732273
23.

Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.

Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J, McCluskey K, Whitman E, Agarwala S, Siskin G, Nutting C, Toomey MA, Webb C, Beresnev T, Pingpank JF.

Ann Surg Oncol. 2016 Apr;23(4):1309-19. doi: 10.1245/s10434-015-4968-3. Epub 2015 Nov 23.

PMID:
26597368
24.

Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.

Liu S, Staats P, Lee M, Alexander HR, Burke AP.

Pathology. 2014 Dec;46(7):604-9. doi: 10.1097/PAT.0000000000000181.

PMID:
25393250
25.

Isolated hepatic perfusion for patients with liver metastases.

Reddy SK, Kesmodel SB, Alexander HR Jr.

Ther Adv Med Oncol. 2014 Jul;6(4):180-94. doi: 10.1177/1758834014529175. Review.

26.

Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Reddy SK, Reilly C, Zhan M, Mindikoglu AL, Jiang Y, Lane BF, Alexander HR, Culpepper WJ, El-Kamary SS.

Med Oncol. 2014 Jun;31(6):971. doi: 10.1007/s12032-014-0971-y. Epub 2014 May 6.

27.

Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders.

Reddy SK, Zhan M, Alexander HR, El-Kamary SS.

World J Gastroenterol. 2013 Dec 7;19(45):8301-11. doi: 10.3748/wjg.v19.i45.8301.

28.

Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer.

Zhang G, He P, Tan H, Budhu A, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Maitra A, Hanna N, Alexander HR, Hussain SP.

Clin Cancer Res. 2013 Sep 15;19(18):4983-93. doi: 10.1158/1078-0432.CCR-13-0209. Epub 2013 Aug 5.

29.

Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.

Lee M, Alexander HR, Burke A.

Pathology. 2013 Aug;45(5):464-73. doi: 10.1097/PAT.0b013e3283631cce.

PMID:
23846294
30.

FOXL1, a novel candidate tumor suppressor, inhibits tumor aggressiveness and predicts outcome in human pancreatic cancer.

Zhang G, He P, Gaedcke J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Hanna N, Alexander HR, Hussain SP.

Cancer Res. 2013 Sep 1;73(17):5416-25. doi: 10.1158/0008-5472.CAN-13-0362. Epub 2013 Jun 25.

31.

Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States.

Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J.

Ann Surg Oncol. 2014 May;21(5):1501-5. doi: 10.1245/s10434-013-3061-z. Epub 2013 Jun 21. Review.

PMID:
23793364
32.

Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.

Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y.

Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13.

33.

Regional therapies for cancer.

Gamblin TC, Alexander HR, Edwards R, Bartlett DL.

Ann Surg Oncol. 2013 Apr;20(4):1053-5. doi: 10.1245/s10434-013-2873-1. No abstract available.

PMID:
23456388
34.
35.

Multipotent cancer stem cells derived from human malignant peritoneal mesothelioma promote tumorigenesis.

Varghese S, Whipple R, Martin SS, Alexander HR.

PLoS One. 2012;7(12):e52825. doi: 10.1371/journal.pone.0052825. Epub 2012 Dec 28.

36.

A novel nomogram for peritoneal mesothelioma predicts survival.

Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.

Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12.

37.

Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction.

Bellavance EC, Alexander HR Jr.

J Clin Oncol. 2012 Dec 10;30(35):4290-1. doi: 10.1200/JCO.2012.45.0536. Epub 2012 Oct 29. No abstract available.

PMID:
23109693
38.

von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms.

Turcotte S, Turkbey B, Barak S, Libutti SK, Alexander HR, Linehan WM, Hughes MS, Nilubol N, Gesuwan K, Millo C, Quezado M, Choyke PL, Kebebew E, Phan GQ.

Surgery. 2012 Dec;152(6):1106-17. doi: 10.1016/j.surg.2012.08.010. Epub 2012 Oct 27.

39.

Value of surgery in patients with negative imaging and sporadic Zollinger-Ellison syndrome.

Norton JA, Fraker DL, Alexander HR, Jensen RT.

Ann Surg. 2012 Sep;256(3):509-17. doi: 10.1097/SLA.0b013e318265f08d.

40.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

41.

18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.

Cao Q, Lu M, Heath J, Hausner PF, Alexander HR, Dilsizian V, Chen W.

Clin Nucl Med. 2012 May;37(5):492-4. doi: 10.1097/RLU.0b013e3182478bb5.

PMID:
22475902
42.

DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.

Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM, Ried T, Hassan R, Yfantis HG, Lee DH, Lacy C, Maitra A, Hanna N, Alexander HR, Hussain SP.

PLoS One. 2012;7(2):e31507. doi: 10.1371/journal.pone.0031507. Epub 2012 Feb 20.

43.

Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma.

Turner K, Varghese S, Alexander HR Jr.

J Natl Compr Canc Netw. 2012 Jan;10(1):49-57. Review.

PMID:
22223869
44.

Ethical considerations in clinical research.

Bellavance EC, Alexander HR.

Ann Surg Oncol. 2012 Feb;19(2):355-6. doi: 10.1245/s10434-011-2143-z. No abstract available.

PMID:
22086446
45.

A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.

Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, Royal RE, Alexander HR, Seidel G, Steinberg SM, Shuttack Y, Libutti SK.

Oncology. 2010;79(5-6):382-8. doi: 10.1159/000323488. Epub 2011 Mar 25.

46.

Surgery for peritoneal mesothelioma.

Turner KM, Varghese S, Alexander HR Jr.

Curr Treat Options Oncol. 2011 Jun;12(2):189-200. doi: 10.1007/s11864-011-0151-7.

PMID:
21445576
47.

Introduction: Endocrine cancers.

Alexander HR Jr, Pacak K.

Semin Oncol. 2010 Dec;37(6):556. doi: 10.1053/j.seminoncol.2010.10.009. No abstract available.

48.

Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.

Libutti SK, Paciotti GF, Byrnes AA, Alexander HR Jr, Gannon WE, Walker M, Seidel GD, Yuldasheva N, Tamarkin L.

Clin Cancer Res. 2010 Dec 15;16(24):6139-49. doi: 10.1158/1078-0432.CCR-10-0978. Epub 2010 Sep 27.

49.

Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr.

Cancer. 2011 Jan 15;117(2):361-71. doi: 10.1002/cncr.25555. Epub 2010 Sep 13.

50.

Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease.

Mathur A, Kemp CD, Dutta U, Baid S, Ayala A, Chang RE, Steinberg SM, Papademetriou V, Lange E, Libutti SK, Pingpank JF, Alexander HR, Phan GQ, Hughes M, Linehan WM, Pinto PA, Stratakis CA, Kebebew E.

J Am Coll Surg. 2010 Sep;211(3):384-90. doi: 10.1016/j.jamcollsurg.2010.05.006. Epub 2010 Jul 14.

Supplemental Content

Loading ...
Support Center